0000832101-26-000009
SEC filingStrong start to fiscal 2026 with double-digit earnings growth driven by AI-related demand in HST, though life sciences weakness and tariff uncertainty temper the outlook.
Organic sales for the three months ended March 31, 2026 reflect higher volumes primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense, partially offset by lower volumes in the Company’s life sciences businesses. This dynamic underpinned the 8.9% year-over-year revenue growth to $886.9M.
Operating income increased 21.4% to $172.4M, with operating margin expanding to 19.4%. The improvement was driven by volume leverage and favorable price/cost, partially offset by unfavorable mix and the impact of acquisitions. Adjusted EBITDA margin also increased, primarily due to net productivity improvements and volume leverage, though unfavorable mix and volume deleverage were partial offsets. Gross margin contracted to 44.9% as unfavorable mix and price/cost pressure outweighed productivity gains.
Net cash provided by operating activities was $103.7M, compared to $105.7M in the prior year period. Capital expenditures increased to $17.7M from $14.3M, reflecting investments to support planned production. Free cash flow of $86.0M provided ample liquidity for dividends and other capital allocation priorities. The Company believes it has sufficient operating cash flows to continue to meet current obligations and invest in planned capital expenditures.
While segment-level financials are not separately disclosed in this narrative, the business context indicates that the HST segment benefited from AI-driven demand and defense strength, while life sciences remained a drag. The Company’s measurements of segment performance include net sales, Adjusted EBITDA, and Adjusted EBITDA margin.
Management did not provide quantitative guidance but expressed confidence in sufficient operating cash flows to meet obligations and invest in planned capital expenditures. The company is monitoring tariff developments and expects to mitigate potential unfavorable impacts. Key risks include ongoing weakness in life sciences, project timing in dispensing, and the broader industrial activity levels that influence demand for IDEX's products. The company's strong liquidity position and conservative leverage provide a buffer against near-term uncertainties.